Skip to main content

Table 1 Incidence of notified pertussis, vaccines, vaccination schedules and coverage in Spain and Dominican Republic, 2005–2014

From: Epidemiology of pertussis in two Ibero-American countries with different vaccination policies: lessons derived from different surveillance systems

Country Global Incidence per 100,000 inhab.a Incidence per 100,000 inhab. ≤1 year-old Vaccine Manufacturer Global coverageb (%) Vaccination Schedulec (type vaccine)
Spain (Iberian country) 3.4 (0.5–8,4) 813.3 Infanrix Hexa®
Infanrix VPI Hib®
Pentavac®
GlaxoSmithKline Biologicals, S.A.
Sanofi Pasteur MSD, S.A.
96.5 Primary: 2, 4, 6 mo.
Booster: 15–18 mo and 4–6 yr (DTaP)
DR (Caribbean country) 12.1 (1.0–37.0) 132.0 Quinvaxem®
Tritanrix® HB
DTCHepB.Hib®
GlaxoSmithKline Biologicals, S.A. 82.2 Primary: 2, 4, 6 mo.
Booster: 18 mo and 4 yr (DTwP)
  1. aCare should be taken when comparing incidences between countries because of the different surveillance and diagnostic methods used
  2. bcoverage in children aged 2, 4 and 6 months (primary series coverage in children)
  3. ctwo booster doses are given in DR and Spain at the age of 18 months and 4 years-old, and between 4–6 years